Category Archives: Patents

Trump’s Executive Order on Drug Prices Might Be More in Favour of Drug Companies

The order will likely be a far cry from the president’s previous remarks about the pharmaceutical industry. Emily Kopp has a big scoop for Kaiser Health News. She has obtained a six-page document outlining the draft provisions or objectives of a proposed presidential executive … Continue reading

Posted in Drug prices, Patent, Patent Term Extension, Uncategorized | Leave a comment

Intellectual property, affordable medicine, and universal health care

By Dr. Maria Guevara, Business world online| May 05, 2017 MANILA IS SET to host the 18th round of the multilateral trade deal — the Regional Comprehensive Economic Partnership (RCEP) that encompasses 50% of the global population.  With the Philippines … Continue reading

Posted in IPR, Patent, Patents, Regional Comprehensive Economic Partnership, TPP, TRIPS, Uncategorized | Leave a comment

MSF response on RCEP negotiations in the Philippines

Source: MSF Access Campaign New Delhi, 8 May 2017 – The Philippines is set to host the 18th round of the Regional Comprehensive Economic Partnership (RCEP) trade agreement’s negotiations in Manila this week. Negotiators from the ten members of the … Continue reading

Posted in Data Exclusivity, Evergreening, Investor state dispute, IPR Enforcement, ISDS, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, Uncategorized, WTO | Leave a comment

Hepatitis drug patent application opposed

A health advocacy group voiced its opposition Tuesday to a patent application for hepatitis C medicine, Sofosbuvir, filed with the Department of Intellectual Property’s Patent Office, which the group said was unjustified. If approved, the drug patent would bar fair … Continue reading

Posted in Hepatitis C, Patent Opposition, Sofosbuvir, Uncategorized | Leave a comment

Avoid Patent Clauses in Trade Treaties that can Kill Millions

By Martin Khor, Inter Press Service | February 27, 2017 PENANG, Feb 27 2017 (IPS) – Recently a very interesting article on why there are inequalities in access to health care and how  medicine prices are beyond the reach of many … Continue reading

Posted in Data Exclusivity, FTA, Patent Term Extension, TPP, TRIPS, TRIPS flexibilities, TRIPS plus, TRIPS&IP rights, Uncategorized | Leave a comment

RCEP and Health: This Kind of ‘Progress’ is Not What India and the World Need

Source: The Wire Concerns remain over the impact of RCEP negotiations on public health and access to medicines Negotiators from 16 countries are meeting in Kobe, Japan on Monday to begin the 17th round of negotiations of the Regional Comprehensive Economic … Continue reading

Posted in Data Exclusivity, Investor state dispute, IPR, Patent, Patent Term Extension, TRIPS flexibilities, TRIPS plus, TRIPS&IP rights, Uncategorized | Leave a comment

Civil society, patient groups call on Japan and South Korea to withdraw harmful proposals from RCEP negotiations

By Ramesh Shankar, http://www.pharmabiz.com | February 24, 2017 As 16 countries negotiating the Regional Comprehensive Economic Partnership (RCEP) agreement meet next week in Kobe, Japan, for the seventeenth round of negotiations, civil society and patient groups, including the international medical humanitarian … Continue reading

Posted in Data Exclusivity, IPR, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TPP, Uncategorized | Leave a comment